What is Aptevo Therapeutics Inc (APVO) stock price today?

Aptevo Therapeutics Inc (APVO) currently trades at $4.81 per share. The stock has a market capitalization of $5.68M and a P/E ratio of —x.

Is APVO stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Aptevo Therapeutics Inc has a Smart Value Score of 29/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is -27.19.

What is the APVO stock price target for 2026?

WallStSmart's 12-month price target for Aptevo Therapeutics Inc is $52,755.76.

Is Aptevo Therapeutics Inc financially healthy?

Aptevo Therapeutics Inc's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of -27.19 places it in the distress.

APVO

Aptevo Therapeutics Inc

NASDAQ: APVO · HEALTHCARE · BIOTECHNOLOGY

$4.81

-1.94% today

Updated 2026-04-29

Market cap

$5.68M

P/E ratio

—

P/S ratio

2.70x

EPS (TTM)

$-87.27

Dividend yield

—

52W range

$4 – $189

Volume

0.1M

Market cap

$5.68M

P/E ratio

—

P/S ratio

2.70x

EPS (TTM)

$-87.27

Dividend yield

—

52W range

$4 – $189

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.7

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-27.2

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$21.00

+336.59%

12-Month target

$52,755.76

+1096693.35%

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.23x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -27.19 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-5.24M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$3.11M	$0.00	$0.00	$0.00	$-220000.00
Net income	$8.03M	$-17.41M	$-24.13M	$-25.97M	$-5.81M
EPS	—	—	—	—	$-87.27
Free cash flow	$-21.05M	$-11.73M	$-23.79M	$-25.59M	$-5.24M
Profit margin	257.77%	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
APVO	$5.68M	29	3.7	3.0	5.0	6.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Aptevo Therapeutics Inc trades at $4.81. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -27.19, it sits in the distress.

Frequently asked questions

What is Aptevo Therapeutics Inc's stock price?

Aptevo Therapeutics Inc (APVO) trades at $4.81.

Is Aptevo Therapeutics Inc overvalued?

Smart Value Score 29/100 (Grade F, Strong Sell).

What is the price target of Aptevo Therapeutics Inc (APVO)?

The analyst target price is $21.00, representing +336.6% upside from the current price of $4.81.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

-27.19 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

aptevotherapeutics.com

Quick metrics

P/S ratio2.70x

ROE-234.60%

Beta1.51

50D MA$5.26

200D MA$20.59

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

APVO vs LLY →APVO vs JNJ →APVO vs ABBV →Stock screener →